Janus Kinase Inhibitor

For patients with rheumatoid arthritis and inadequate response to JAK inhibitors, cycling to another JAK inhibitor is a more effective option than switching to a biological disease-modifying antirheumatic drug, according to data.

MIAMI BEACH, Fla. — Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no increased safety risks, according to data published in Arthritis Research & Therapy.

A once-daily dose of ivarmacitinib reduced disease activity and improved function among patients with rheumatoid arthritis through 52 weeks, according to phase 3 trial results published in Annals of the Rheumatic Diseases.

WASHINGTON — In this video, Namrata Singh, MD, MSCI, spotlights three important abstracts in rheumatoid arthritis presented at ACR Convergence 2024.

PHILADELPHIA — Use of Janus kinase inhibitors did not increase the risk for major cardiovascular or thromboembolic events among patients with inflammatory bowel disease compared with anti-tumor necrosis factor therapy, data showed.

This month’s Healio Exclusive highlights the efficacy of Janus kinase inhibitors in the management of ulcerative colitis and Crohn’s disease.

Despite an existing class-wide black box warning, 45% of health care providers felt cardiovascular concerns related to Janus kinase inhibitors “were irrelevant” to patients with inflammatory bowel disease, according to survey results.

Zasocitinib, a potent and selective tyrosine kinase 2 inhibitor, safely and effectively cleared psoriasis in a high proportion of patients, according to a study.